Shire PLC Company Profile (NASDAQ:SHPG)


Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web:
Average Prices:
  • 52 Week Range: $139.36 - $209.22
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.67
  • P/E Growth: 0.00
  • Annual Dividend: $0.91
  • Dividend Yield: 0.6%
  • Net Margins: 4.70%
  • Return on Equity: 14.10%
  • Return on Assets: 6.25%
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 0.96%
  • Quick Ratio: 0.52%
  • Beta: 1.6

Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC declared a semiannual dividend on Friday, August 11th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share on Friday, October 20th. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) released its earnings results on Thursday, August, 3rd. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.53 by $0.20. The business earned $3.75 billion during the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Shire PLC's revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.38 earnings per share. View Shire PLC's Earnings History.

When will Shire PLC make its next earnings announcement?

Shire PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Shire PLC.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

21 brokerages have issued 1-year target prices for Shire PLC's shares. Their predictions range from $159.00 to $325.00. On average, they anticipate Shire PLC's share price to reach $220.91 in the next twelve months. View Analyst Ratings for Shire PLC.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
  • 2. According to Zacks Investment Research, "Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry." (8/8/2017)
  • 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Are investors shorting Shire PLC?

Shire PLC saw a increase in short interest in July. As of July 14th, there was short interest totalling 1,247,044 shares, an increase of 34.9% from the June 30th total of 924,373 shares. Based on an average daily trading volume, of 1,330,164 shares, the days-to-cover ratio is presently 0.9 days.

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director
  • Jeffrey Poulton, Chief Financial Officer, Executive Director
  • William Mordan, General Counsel, Company Secretary
  • Perry Sternberg, Head - U.S. Commercial
  • Kim Stratton, Head - International Commercial
  • Philip J. Vickers, Head - Research and Development
  • Matthew Walker, Head - Technical Operations
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
  • Olivier Bohuon, Non-Executive Director
  • Ian T. Clark, Non-Executive Director

Who owns Shire PLC stock?

Shire PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (0.00%), Maverick Capital Ltd. (0.00%), Glenview Capital Management LLC (0.00%), FMR LLC (0.53%), Ameriprise Financial Inc. (0.51%) and Vanguard Group Inc. (0.49%). View Institutional Ownership Trends for Shire PLC.

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Voya Investment Management LLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Sphera Funds Management LTD., Sei Investments Co. and Capital Fund Management S.A.. View Insider Buying and Selling for Shire PLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenview Capital Management LLC, Northern Trust Corp, OZ Management LP, Maverick Capital Ltd., Harding Loevner LP, Ameriprise Financial Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Shire PLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately $140.85.

MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  788 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  1,105
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $220.91 (56.84% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017Barclays PLCDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$216.00 -> $206.00LowView Rating Details
8/4/2017Royal Bank Of CanadaSet Price TargetBuy$213.00LowView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$159.00MediumView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
7/12/2017Stifel NicolausReiterated RatingBuy$245.00LowView Rating Details
7/6/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
6/1/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$325.00LowView Rating Details
4/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00N/AView Rating Details
(Data available from 8/21/2015 forward)


Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.61
Q3 20174$3.59$3.89$3.73
Q4 20174$3.75$4.26$4.09
(Data provided by Zacks Investment Research)


Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Next Dividend:10/20/2017
Annual Dividend:$0.91
Dividend Yield:0.65%
Payout Ratio:40.63% (Trailing 12 Months of Earnings)
6.10% (Based on This Year's Estimates)
5.60% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by


Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline logoShire PLC (SHPG) Given "Buy" Rating at Cantor Fitzgerald - August 21 at 3:28 PM logoShire plc Director and Senior Management Changes - August 21 at 10:21 AM logoShire PLC (SHPG) Given Average Rating of "Buy" by Analysts - August 18 at 5:26 PM logoShire Files Marketing Application for Lifitegrast in Europe - Nasdaq ... - Nasdaq - August 17 at 4:37 PM logoShire PLC (SHPG) Research Coverage Started at Evercore ISI - August 16 at 6:26 PM logoShire submits marketing application in Europe for lifitegrast for dry eye disease - August 16 at 7:29 AM logoShire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe - August 16 at 7:29 AM logoShire PLC (SHPG) Earns "Buy" Rating from Cantor Fitzgerald - August 15 at 11:16 AM logoShire applies for European approval of potential blockbuster eye drop - August 15 at 6:56 AM logoShire PLC (NASDAQ:SHPG) Plans $0.15 Semiannual Dividend - August 11 at 6:06 PM logoShire PLC (NASDAQ:SHPG) Lowered to Equal Weight at Barclays PLC - August 11 at 4:04 PM logoShire PLC (NASDAQ:SHPG) to Post FY2017 Earnings of $15.04 Per Share, SunTrust Banks Forecasts - August 10 at 9:32 AM logoShire Becomes Oversold (SHPG) - Nasdaq - August 10 at 7:50 AM logoJefferies Group LLC Reaffirms "Hold" Rating for Shire PLC (SHPG) - August 9 at 3:26 PM logoFY2017 Earnings Forecast for Shire PLC (SHPG) Issued By Cantor Fitzgerald - August 9 at 8:36 AM logoSunTrust Banks Analysts Reduce Earnings Estimates for Shire PLC (SHPG) - August 9 at 7:26 AM logoShire PLC to Post Q4 2017 Earnings of $3.75 Per Share, William Blair Forecasts (SHPG) - August 7 at 8:02 AM logoShire PLC (SHPG) Forecasted to Earn Q2 2017 Earnings of $3.62 Per Share - August 7 at 7:04 AM logoShire PLC (SHPG) Given a $213.00 Price Target by Royal Bank Of Canada Analysts - August 6 at 7:08 PM logoShire PLC (NASDAQ:SHPG) Downgraded to "Strong Sell" at BidaskClub - August 5 at 11:04 AM logoWhy Corporate Spinoffs For Shire And Valeant Make Sense - Seeking Alpha - August 5 at 7:00 AM logoShire Q2/2017: Market Reaction Makes No Sense - Seeking Alpha - August 5 at 7:00 AM logoShire PLC (SHPG) Releases Earnings Results, Beats Expectations By $0.20 EPS - August 5 at 12:22 AM logoBrokers Set Expectations for Shire PLC's Q4 2017 Earnings (NASDAQ:SHPG) - August 4 at 2:38 PM logoEarnings Reaction History: Shire plc, 33.3% Follow-Through Indicator, 2.9% Sensitive - Nasdaq - August 4 at 8:10 AM logoNo Room For Neuroscience In New-Look Shire - Seeking Alpha - August 4 at 8:10 AM logoShire Surges on Baxalta Synergies and Strong Earnings Momentum - August 4 at 8:10 AM logoShire tops Street 2Q forecasts - August 4 at 8:10 AM logo[$$] Shire Mulls Spinning-off or Selling Neuroscience Unit - August 4 at 8:10 AM logoShire Acq Inv Ireland Designated Activity Co -- Moody's: Shire's evaluation of neuroscience franchise credit negative - August 4 at 8:10 AM logo[$$] Lombard: Impatient Shire boss waits for market to catch up - August 4 at 8:10 AM logoShire's ADHD Spinoff Idea Is Shaky - August 4 at 8:10 AM logoShire plc : Half-yearly report - August 4 at 8:10 AM logoShire PLC (NASDAQ:SHPG) Releases FY17 Earnings Guidance - August 3 at 9:26 AM logoZacks: Analysts Expect Shire PLC (NASDAQ:SHPG) Will Announce Quarterly Sales of $3.73 Billion - August 3 at 7:28 AM logoArrow Financial Corp Buys iShares MSCI All Country Asia ex Japan Index Fund, Sherwin-Williams ... - August 2 at 4:26 PM logoShire PLC (NASDAQ:SHPG) Short Interest Update - July 29 at 7:10 AM logoShire Stock Rising on Takeover Talks - - July 28 at 7:55 AM logoShire PLC (NASDAQ:SHPG) to Release Earnings on Thursday - July 27 at 3:48 PM logoShire plc (SHPG) Said Back in Play - Standard - - July 27 at 7:24 AM logoShire Stock Rising on Takeover Talks - July 27 at 7:24 AM logoDrug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics - PR Newswire (press release) - July 26 at 7:32 AM logoDon't Lose The Faith In Shire - Seeking Alpha - July 26 at 7:32 AM logoGap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students - July 26 at 7:32 AM logoShire PLC (SHPG) Given Average Recommendation of "Buy" by Brokerages - July 24 at 5:20 PM logoShire PLC (NASDAQ:SHPG) Expected to Earn FY2017 Earnings of $14.63 Per Share - July 20 at 9:53 AM logoExane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ... - July 20 at 7:42 AM logoFY2018 EPS Estimates for Shire PLC (NASDAQ:SHPG) Decreased by Analyst - July 19 at 1:56 PM logoWilliam Blair Equities Analysts Lower Earnings Estimates for Shire PLC (SHPG) - July 19 at 9:57 AM logoMarinus Pharmaceuticals (MRNS) and Shire PLC (NASDAQ:SHPG) Critical Survey - July 18 at 10:19 PM



Shire PLC (SHPG) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by Staff